At a glance

ClinicalIndex Comparison Record

N/ACompleted· 62 enrolled

Drug / intervention

Individual Deprescribing Interventionother

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03655405

NCT03655405N/ACompleted

Compare CT.gov

Opportunities and Limits to Deprescribing in Nursing Homes: Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents.

Anne Niquille·interventional·Posted Aug 31, 2018·Updated May 19, 2021

In Brief

A clinical study evaluating Individual Deprescribing Intervention for Polypharmacy and Inappropriate Prescribing. Completed, enrolled 62 participants across 1 site.

Detailed Summary

This study will evaluate the effects of a pharmacist-led, deprescribing-focused medication review on the use of inappropriate medications by nursing home residents

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPolypharmacy, Inappropriate Prescribing

CountriesSwitzerland

Collaborators--

Timeline

N/ACompletedFinished

20192020202120222023202420252026

First PostedAug 2018

Enrollment StartOct 2018

Primary CompletionAug 2019

TodayJul 2026

First PostedAug 31, 2018

Enrollment StartOct 30, 2018

Primary CompletionAug 22, 2019

TodayJul 2, 2026

Enrollment to primary: 10 monthsPosted 7.8 years ago

Interventions

Individual Deprescribing Interventionother

The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.